多西紫杉醇联合沙立度胺片二线治疗晚期非小细胞肺癌的临床观察

目的评价多西紫杉醇联合沙立度胺片二线治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法采用同期随机对照方法，共85例晚期复发的NSCLC患者入组。46例患者接受多西紫杉醇联合沙立度胺片二线治疗(治疗组)，39例患者接受多西紫杉醇单药二线治疗(对照组)。结果治疗组和对照组的有效率分别为19.6%和17.9%，疾病控制率分别为65.3%和56.4%，中位无进展生存期(PFS)分别为5月和3月(P=0.029)，中位生存期(OS)分别为9月和6月(P=0.044)。两组常见的不良反应是骨髓抑制、消化道反应、脱发、乏力、关节酸、嗜睡、便秘、水肿及末梢神经炎等，治疗组和对照组的差异无统计学意义(P> 0.05)。结论多西紫杉醇联合沙立度胺片二线治疗期NSCLC，能够延长生存时间，提高生存质量，改善预后，且不良反应无明显增加。

Clinical Observation on Thalidomide Accompanied Docetaxel in Chemotherapy Patients with Advanced Non-small Cell Lung Cancer As Second-line Chemotherapy

Objective To evaluate the therapeutic effects and toxicities of docetaxel plus thalidomide for the treatment of advanced non-small cell lung cancer as second-line chemotherapy.Methods This study was carried out as a prospective,randomized control clinical trial.46 patients with advanced non-small cell lung cancer were scheduled to receive chemotherapy(docetaxel plus thalidomide)as treatment group,39 patients were scheduled to receive chemotherapy(docetaxel only)as control group.Results The median time to disease progression was 5 months and 3 months(P=0.029).The median survival time was 9 months and 6 months(P=0.044).There were statistically significant differences between the two groups(P<0.05).Two groups of common adverse reaction were bone marrow suppression,digestive tract,hair loss,fatigue,reaction joint acid,lethargy,constipation,edema and peripheral neuropathy,etc.The difference of the treatment group and control group was of no statistical significance(P>0.05).ConclusionThalidomide accompanied docetaxel in advanced NSCLC is active effect,it can prolong survival time significantly and improve patient’s life quality.